Micro-X Ltd (ASX: MX1) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Micro-X Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Micro-X Ltd (ASX: MX1)
Latest News
Healthcare Shares
Guess which ASX medical tech share soared 37% at one point today
Broker Notes
Top brokers name 3 ASX small cap shares to buy
Broker Notes
Morgans picks small cap ASX shares with near-term share price catalysts
MX1 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Micro-X Ltd
Micro-X Ltd operates in the medical industry. The company is engaged in the design, development, manufacturing, and sale of ultra-lightweight carbon nanotube-based X-ray products, including core X-ray tubes and high-voltage generator components, for the healthcare, defense, and security markets. Its products include Nano; Rover and Mobile Backscatter Imager (MBI), Mobile Baggage Scanner (MBS), and others. Geographically, it derives a majority of its revenue from the United States and also has a presence in Asia-Pacific, and Europe & EMEA.
MX1 Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
07 Nov 2024 | $0.07 | $0.00 | 0.00% | 235,443 | $0.07 | $0.07 | $0.07 |
06 Nov 2024 | $0.07 | $0.00 | 0.00% | 253,850 | $0.08 | $0.08 | $0.07 |
05 Nov 2024 | $0.07 | $0.00 | 0.00% | 351,624 | $0.07 | $0.07 | $0.07 |
04 Nov 2024 | $0.07 | $0.00 | 0.00% | 138,888 | $0.07 | $0.07 | $0.07 |
01 Nov 2024 | $0.07 | $0.01 | 15.87% | 315,951 | $0.06 | $0.07 | $0.06 |
31 Oct 2024 | $0.06 | $-0.01 | -14.71% | 217,867 | $0.07 | $0.07 | $0.06 |
30 Oct 2024 | $0.07 | $0.00 | 0.00% | 197,322 | $0.07 | $0.07 | $0.07 |
29 Oct 2024 | $0.07 | $0.00 | 0.00% | 254,865 | $0.07 | $0.07 | $0.07 |
28 Oct 2024 | $0.07 | $0.00 | 0.00% | 122,058 | $0.07 | $0.07 | $0.07 |
25 Oct 2024 | $0.07 | $0.00 | 0.00% | 361,660 | $0.07 | $0.07 | $0.07 |
24 Oct 2024 | $0.08 | $0.00 | 0.00% | 29,594 | $0.08 | $0.08 | $0.08 |
23 Oct 2024 | $0.08 | $0.00 | 0.00% | 100 | $0.08 | $0.08 | $0.08 |
22 Oct 2024 | $0.08 | $0.00 | 0.00% | 264,853 | $0.07 | $0.08 | $0.07 |
21 Oct 2024 | $0.07 | $0.00 | 0.00% | 140,745 | $0.07 | $0.08 | $0.07 |
18 Oct 2024 | $0.07 | $0.00 | 0.00% | 161,929 | $0.07 | $0.07 | $0.07 |
17 Oct 2024 | $0.08 | $0.00 | 0.00% | 77,356 | $0.07 | $0.08 | $0.07 |
16 Oct 2024 | $0.07 | $0.00 | 0.00% | 23,346 | $0.07 | $0.07 | $0.07 |
15 Oct 2024 | $0.07 | $0.00 | 0.00% | 95,573 | $0.07 | $0.07 | $0.07 |
14 Oct 2024 | $0.07 | $0.00 | 0.00% | 15,450 | $0.07 | $0.07 | $0.07 |
11 Oct 2024 | $0.07 | $0.00 | 0.00% | 189,799 | $0.07 | $0.07 | $0.07 |
10 Oct 2024 | $0.07 | $0.00 | 0.00% | 239,626 | $0.07 | $0.07 | $0.07 |
09 Oct 2024 | $0.07 | $0.00 | 0.00% | 208,618 | $0.07 | $0.07 | $0.07 |
08 Oct 2024 | $0.07 | $0.00 | 0.00% | 21,473 | $0.07 | $0.07 | $0.07 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
28 Jun 2024 | David Knox | Issued | 269,610 | $31,391 |
Director remuneration.
|
30 May 2024 | James (Jim) McDowell | Issued | 78,947 | $7,263 |
Participation in share purchase plan.
|
30 May 2024 | James (Jim) McDowell | Buy | 157,894 | $15,000 |
Participation in share purchase plan.
|
30 May 2024 | Ilona Meyer | Issued | 52,631 | $4,842 |
Participation in share purchase plan.
|
30 May 2024 | Ilona Meyer | Buy | 105,263 | $10,000 |
Participation in share purchase plan.
|
30 May 2024 | Alexander Gosling | Buy | 263,157 | $25,000 |
Participation in share purchase plan.
|
30 May 2024 | Alexander Gosling | Issued | 131,578 | $12,105 |
Participation in share purchase plan.
|
30 May 2024 | Patrick O'Brien | Issued | 526,316 | $48,421 |
Placement.
|
30 May 2024 | Patrick O'Brien | Buy | 1,052,632 | $100,000 |
Placement.
|
30 May 2024 | David Knox | Buy | 210,526 | $20,000 |
Participation in share purchase plan.
|
30 May 2024 | David Knox | Issued | 105,263 | $9,684 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Alexander Bennett Gosling | Non-Executive Director | Aug 2015 |
Dr Gosling has been working in the field of process and product development and related research and development for 50 years. He was a founding director of Invetech and was part of the management team that led Invetech to a public listing (as Vision Systems) and then to its acquisition by Danaher Corp for $800m. He currently works in technology commercialization, advising universities, mentoring start-ups and sitting on the Boards of early-stage companies.
|
Mr Patrick Gerard O'Brien | Non-Executive Director | Aug 2015 |
Mr O'Brien is also a chairman/board member of several not-for-profit organizations and foundations. Patrick has over 30 years business experience in Australia, the UK, Europe, Asia, and the US including as a Senior Managing Director with Macquarie Group where he led teams in corporate finance and private equity (London 2005-2009). In this latter role Patrick was responsible for Macquarie's controlling stakes in, and chaired, unlisted groups European Directories and National Grid Wireless. Prior to Macquarie, Patrick was a strategy consultant with McKinsey & Company and a lawyer with Minter Ellison. He is member of Risk Committee.
|
Mr David Knox | Non-Executive DirectorNon-Executive Chairman | Apr 2020 |
Mr Knox was Managing Director and Chief Executive Officer of Australian Naval Infrastructure, a Government Business Enterprise responsible for the delivery of naval infrastructure required to support the Commonwealth's continuous shipbuilding program, including the Osborne South Shipyard. David was previously Managing Director & Chief Executive Officer of Santos from March 2008 through until his retirement in December 2015. He is member of the Risk Committee.
|
Mr James (Jim) White McDowell | Non-Executive Director | Jan 2021 |
Mr McDowell has more than 30 years of experience in international defense and aerospace sectors and has lived and worked in the UK, the USA, Korea, Singapore, Hong Kong and Australia. Prior to this he was Chief Executive Officer of BAE Systems Australia for 10 years. Based in Adelaide, he drove an expansion program as the Group grew to become Australia's defense business. Prior to his time at BAE Systems Jim worked for 18 years at aerospace Group Bombardier Shorts in legal, commercial and marketing positions, contributing to that Group's growth into the USA.
|
Ms Ilona Meyer | Non-Executive Director | Mar 2022 |
Ms Meyer has over 25 years of experience as a senior executive in healthcare, agriculture and emerging technologies focusing on innovation and growth. Ilona is General Counsel and Company Secretary for Nuix Limited and prior to this role has held multiple executive roles with private and public companies, including ASX-listed companies and growth start-ups, leading business transformation initiatives, managing multiple stakeholders, as well as navigating high profile litigation and regulatory disputes. Prior to commencing her current role at Nuix, Ilona was General Counsel and Head of Legal & Compliance of the Boehringer Ingelheim Group for the Australian and New Zealand division. She is also Chair of Risk Committee.
|
Mr Andrew Hartmann | Non-Executive Director | Dec 2022 |
Mr Hartmann is the Senior Vice President and GM Imaging Solutions at Varex Imaging Corporation and has worked overseas and in global senior roles for more than 30 years. Andrew has business expertise in the field of medical imaging devices with experience working in global roles with a focus on sales, marketing and business operations. Over his career he has been responsible for building brand, market share and bottom-line gains through cost saving and efficiency improvements. Andrew has held senior global management roles at Phillips, Carestream and Siemens, after working in Australia that included building brands across the Asia Pacific region, the United States and Europe.
|
Mr Kingsley Hall | Company SecretaryChief Executive Officer | Feb 2020 |
-
|
Brian Gonzales | CEO Americas & Chief Scientific Officer |
-
|
|
Anthony Skeats | Chief Operating Officer |
-
|
|
Kingsley Hall | Company SecretaryChief Executive Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 74,652,164 | 12.84% |
Varex Imaging Corporation | 54,130,053 | 9.31% |
UBS Nominees Pty Ltd | 45,053,092 | 7.75% |
Citicorp Nominees Pty Ltd | 40,218,556 | 6.92% |
BNP Paribas Nominees Pty Ltd (DRP) | 17,973,718 | 3.09% |
JP Morgan Nominees Australia Pty Ltd | 16,143,660 | 2.78% |
Mr Peter Robin Rowland | 14,194,697 | 2.44% |
BNP Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) | 13,176,047 | 2.27% |
TLFTC Pty Ltd (The Lonsdale Fund A/C) | 6,957,233 | 1.20% |
Charli Jordan Pty Ltd (Molloy Settlement A/C) | 5,115,789 | 0.88% |
Mr Lennie Franklin David | 4,966,867 | 0.85% |
Harman Nominees Pty Ltd (Harmanis Investment A/C) | 4,816,556 | 0.83% |
Bronte Investments Pty Ltd (Mcmahon Superannuation A/C) | 4,600,279 | 0.79% |
Meddiscope Pty Ltd (Podesta Family A/C) | 3,244,565 | 0.56% |
Gowing Bros Limited | 3,068,647 | 0.53% |
Dr Russell Kay Hancock | 3,000,000 | 0.52% |
Anglesea Investments Pty Ltd (Damien O'Brien Family A/C) | 2,766,379 | 0.48% |
Vaben Pty Ltd (The Vaben Superannuation A/C) | 2,765,931 | 0.48% |
Mr Aditya Agarwal | 2,656,164 | 0.46% |
Antipodean Nominees Pty Ltd (Antipodean Family A/C) | 2,484,026 | 0.43% |